• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药品的价格何时不合理?平均终生收入标准。

When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard.

机构信息

Ezekiel J. Emanuel (

出版信息

Health Aff (Millwood). 2019 Apr;38(4):604-612. doi: 10.1377/hlthaff.2018.05052.

DOI:10.1377/hlthaff.2018.05052
PMID:30933574
Abstract

The majority of Americans believe that lowering drug prices should be the top health care priority for the federal government. Yet drug costs as a proportion of the country's medical expenditures have increased substantially in recent years. Because drugs are basic necessities, and because how much society should contribute toward providing basic necessities is a question of justice, policies regarding drug prices must fulfill principles of justice, not just economic efficiency. In this article I define a standard for when the price of a drug is unjust, using a cross-disciplinary ethical approach. Based on four principles, I propose the average lifetime earnings standard for affordability. According to this standard, a drug price is unfair if it exceeds 11 percent of the average American's disposable income. This suggests that current prices for many drugs are excessive and unjust.

摘要

大多数美国人认为,降低药品价格应该是联邦政府医疗保健的首要任务。然而,近年来,药品成本在该国医疗支出中的占比大幅上升。由于药品是基本必需品,以及社会应为提供基本必需品做出多少贡献是一个正义问题,因此药品价格政策必须符合正义原则,而不仅仅是经济效率原则。在本文中,我使用跨学科的伦理方法来定义药品价格不公正的标准。基于四个原则,我提出了可负担性的平均终身收入标准。根据这一标准,如果药品价格超过美国人平均可支配收入的 11%,则该价格是不公平的。这表明目前许多药品的价格过高且不合理。

相似文献

1
When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard.药品的价格何时不合理?平均终生收入标准。
Health Aff (Millwood). 2019 Apr;38(4):604-612. doi: 10.1377/hlthaff.2018.05052.
2
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.美国处方药价格居高不下:根源与改革前景。
JAMA. 2016;316(8):858-71. doi: 10.1001/jama.2016.11237.
3
Higher Drug Prices from Anticompetitive Conduct: Three Case Studies.反竞争行为导致的药品价格上涨:三个案例研究
J Leg Med. 2019 Apr-Jun;39(2):151-167. doi: 10.1080/01947648.2019.1645540.
4
OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.在美国销售的骨质疏松症药物:仿制药竞争、定价结构及支付方之间的差异
Int J Technol Assess Health Care. 2016 Jan;32(6):385-392. doi: 10.1017/S0266462316000623. Epub 2017 Jan 9.
5
International trade and determinants of price differentials of insulin medicine.胰岛素药物的国际贸易与价格差异的决定因素
Health Policy Plan. 2017 Feb;32(1):1-10. doi: 10.1093/heapol/czw085. Epub 2016 Jun 26.
6
Problems in the regulatory policy of the drug market.药品市场监管政策中的问题。
Rev Saude Publica. 2015;49:35. doi: 10.1590/s0034-8910.2015049005779.
7
European healthcare policies for controlling drug expenditure.欧洲控制药品支出的医疗政策。
Pharmacoeconomics. 2003;21(2):89-103. doi: 10.2165/00019053-200321020-00002.
8
The ethics and economics of pharmaceutical pricing.药品定价的伦理与经济问题。
Annu Rev Pharmacol Toxicol. 2015;55:191-206. doi: 10.1146/annurev-pharmtox-010814-124649. Epub 2014 Aug 13.
9
Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control policies.为了对价格管制政策进行有意义的评估,需要开展更好的药品价格比较研究。
Value Health. 2008 Jan-Feb;11(1):129-30. doi: 10.1111/j.1524-4733.2007.00300.x. Epub 2007 Dec 27.
10
International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.国际药品支出控制:法国、德国、瑞典和英国。
Health Care Financ Rev. 1994 Spring;15(3):127-40.

引用本文的文献

1
Moving beyond biology: the critical role of social and structural determinants in atopic dermatitis.超越生物学范畴:社会和结构决定因素在特应性皮炎中的关键作用。
Int J Dermatol. 2025 Feb;64(2):272-281. doi: 10.1111/ijd.17491. Epub 2024 Sep 16.
2
Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.阵发性睡眠性血红蛋白尿症治疗中单克隆抗体的安全性概况及后续药物研发。
Medicina (Kaunas). 2024 Feb 24;60(3):379. doi: 10.3390/medicina60030379.
3
Drug costs in context: assessing drug costs in cost-of-illness analyses.
疾病成本背景下的药品成本:在疾病成本分析中评估药品成本
Drugs Context. 2022 Jul 21;11. doi: 10.7573/dic.2022-5-4. eCollection 2022.
4
A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.增加新药研发和分配的价值和公平性的提案。
Int J Health Serv. 2022 Jul;52(3):363-371. doi: 10.1177/00207314221100647. Epub 2022 May 12.
5
Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?中国基于卫生技术评估的定价谈判:更有效的靶向抗癌药物是否意味着更高的谈判价格?
Health Res Policy Syst. 2022 Jan 3;20(1):3. doi: 10.1186/s12961-021-00810-1.
6
The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease-2019 Treatments Available and Affordable.使潜在的2019冠状病毒病治疗方法可及且可负担的经济与公共卫生必要性。
Value Health. 2020 Nov;23(11):1427-1431. doi: 10.1016/j.jval.2020.04.1824. Epub 2020 May 21.
7
Multiples of Median Income: A Tool to Call out Drugs that are High Cost and Low Value.中位数收入倍数:一种识别高成本低价值药物的工具。
Perm J. 2020;24. doi: 10.7812/TPP/19.080. Epub 2019 Nov 15.